- Home
- ASRT vs IGMS Comparison
ASRT vs IGMS Comparison
Compare ASRT & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- IGMS
- Stock Information
- Founded
- ASRT 1995
- IGMS 1993
- Country
- ASRT United States
- IGMS United States
- Employees
- ASRT N/A
- IGMS N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- IGMS Health Care
- Exchange
- ASRT Nasdaq
- IGMS Nasdaq
- Market Cap
- ASRT 78.3M
- IGMS 82.1M
- IPO Year
- ASRT 1997
- IGMS 2019
- Fundamental
- Price
- ASRT $0.67
- IGMS $1.17
- Analyst Decision
- ASRT Strong Buy
- IGMS Hold
- Analyst Count
- ASRT 3
- IGMS 8
- Target Price
- ASRT $3.08
- IGMS $6.14
- AVG Volume (30 Days)
- ASRT 419.7K
- IGMS 200.2K
- Earning Date
- ASRT 03-12-2025
- IGMS 03-06-2025
- Dividend Yield
- ASRT N/A
- IGMS N/A
- EPS Growth
- ASRT N/A
- IGMS N/A
- EPS
- ASRT N/A
- IGMS N/A
- Revenue
- ASRT $124,961,000.00
- IGMS $2,679,000.00
- Revenue This Year
- ASRT $0.96
- IGMS $134.71
- Revenue Next Year
- ASRT $12.72
- IGMS $74.27
- P/E Ratio
- ASRT N/A
- IGMS N/A
- Revenue Growth
- ASRT N/A
- IGMS 25.77
- 52 Week Low
- ASRT $0.67
- IGMS $1.12
- 52 Week High
- ASRT $1.80
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- ASRT 33.74
- IGMS 33.91
- Support Level
- ASRT $0.70
- IGMS $1.17
- Resistance Level
- ASRT $0.75
- IGMS $1.31
- Average True Range (ATR)
- ASRT 0.05
- IGMS 0.08
- MACD
- ASRT -0.00
- IGMS 0.04
- Stochastic Oscillator
- ASRT 3.02
- IGMS 14.52
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.